Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Ventyx Biosciences logo — company profile

Ventyx Biosciences

Founded 2018 United States San Diego, United States 242 employees Post-IPO Equity Total: $441.60M Biopharma, Biotechnology

General Information

Company Name Ventyx Biosciences
Founded Year 2018
Location United States San Diego, United States
Employees 242
Industries Biopharma, Biotechnology
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Ventyx Biosciences. To contact Ventyx Biosciences, visit ventyxbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Ventyx Biosciences compare?

A PDF of Ventyx Biosciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Ventyx Biosciences soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Ventyx Biosciences

Ventyx Biosciences is a biotechnology company founded in 2018. It has a diverse portfolio of highly differentiated clinical and pre-clinical stage programs targeting high-value areas. The company's combined assets originate from three separate entities: Oppilan Pharma, focusing on S1P1R; Zomagen Biosciences, targeting NLRP3 and the inflammasome; and Ventyx Biosciences, which aims at TYK2. However, the company has been the subject of fraudulent recruitment activities. Unsuspecting individuals have reported receiving unsolicited job offers from individuals posing as Ventyx employees. They exploit victims by soliciting personal and financial information. The company has issued an alert to raise awareness about these fraudulent activities and has provided guidelines to verify the legitimacy of job offers. Furthermore, the FBI has issued a warning about cybercriminals involved in similar scams. Ventyx Biosciences secured a $100.00M Post-IPO Equity investment on 07 March 2024. The investors participating in this round included Redmile Group, Cormorant Asset Management, Surveyor Capital, and Farallon Capital Management. The company is headquartered in the United States. Overall, Ventyx Biosciences showcases promising biotechnological advancements, although the company faces challenges related to fraudulent activities. The recent large-scale investment indicates strong investor confidence in the company's future prospects.

Taxonomy: clinical stage programs, inflammatory diseases, autoimmune disorders, TYK2 inhibitor, S1P1 receptor modulator, ulcerative colitis, NLRP3 inflammasome, phase 1 clinical trials, phase 2 clinical trials, drug development, fraud alert, cybercrime, FBI warning, pharmaceutical industry

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $100.00M 4
Redmile Group Cormorant Asset Management
Redmile Group, Cormorant Asset Management +2
07 Mar 2024
Post IPO Equity $176.60M 6
Boxer Capital Redmile Group CaaS Capital Management
Boxer Capital, Redmile Group +4
19 Sep 2022
Series B $51.00M -
20 Sep 2021
Series A $114.00M -
09 Mar 2021

Ventyx Biosciences Alternatives & Competitors

View All Alternatives
Ventyx Biosciences vs
Shaperon
Shaperon Korea South

Delivering the future of IMMUNOLOGY

Series C
23 employees
Biopharma, Biotechnology
Ventyx Biosciences vs
Zura Bio Limited (Nasdaq: ZURA)
Zura Bio Limited (Nasdaq: ZURA) United States

Developing novel medicines for severe immune disorders

Post-IPO Equity
51 employees
Biopharma, Biotechnology
Ventyx Biosciences vs
AM-Pharma
AM-Pharma The Netherlands

AM-Pharma’s ilofotase alfa is being developed as potential enzyme replacement therapy for adult hypo...

Venture round
31 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Ventyx Biosciences

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Our deep expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated smal...
Ventyx Biosciences was founded in 2018.
Ventyx Biosciences is headquartered in San Diego, United States.
Ventyx Biosciences operates in Biopharma and Biotechnology. Its work centres on clinical stage programs, inflammatory diseases, autoimmune disorders and TYK2 inhibitor.
Ventyx Biosciences has approximately 242 employees.
Ventyx Biosciences has completed 4 funding rounds, raising a total of $441.60M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Ventyx Biosciences include Shaperon, Zura Bio Limited (Nasdaq: ZURA), AM-Pharma, BioAge Labs, BBB Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ventyx Biosciences and Shaperon are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ventyx Biosciences, https://bouncewatch.com/company/ventyx-biosciences, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes